RNA transfection

Anima Biotech to Present at Multiple Scientific and Investor Conferences in September

Retrieved on: 
Tuesday, September 21, 2021
Publication, RNA transfection, Neoplasm, Infection, Lilly, Development, Takeda Pharmaceutical Company, AI, Membrane protein, Entrepreneurship, Drug development, Science, Automation, Chemistry, Lightning, Pharma, RSV, GLOBE, Pharmaceutical industry

Yochi Slonim, Co-Founder and Chief Executive Officer of Anima Biotech, will provide a corporate update during the UBS Biotechnology Private Company Symposium on Sep. 22 at 12:30 p.m.

Key Points: 
  • Yochi Slonim, Co-Founder and Chief Executive Officer of Anima Biotech, will provide a corporate update during the UBS Biotechnology Private Company Symposium on Sep. 22 at 12:30 p.m.
  • Anima Biotech is advancing mRNA Lightning, a novel platform for the discovery of selective small molecule mRNA drugs and their mechanisms of action.
  • With our tremendous expertise in mRNA biology, we were able to advance them at unprecedented speed and success rate.
  • Our science was further validated with seven patents, 15 peer reviewed publications and 17 scientific collaborations.

Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from September 20, 2021

Retrieved on: 
Tuesday, September 21, 2021
Securities Act of 1933, Gene editing, RNA transfection, Cambridge Street Tramways, Lists of diseases, Security (finance), Conference, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Cancer, Webcast, Patient, Investor relations, Head, Acquisition, Terminology, International, Growth, Tornado, Liver, COVID-19, Technology, Brain, Survival, Safety, Forward-looking statement, Degenerative disease, Securities Exchange Act of 1934, NYSE, Eye, GLOBE, Pharmaceutical industry, Medical device

NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc .

Key Points: 
  • NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc .
  • The call was based on Brooklyns most recent corporate slide deck, which can be found here .
  • The webcast can also be replayed until December 20, 2021 at https://services.choruscall.com/mediaframe/webcast.html?webcastid=FBeOvP50 or on Brooklyns website in the Investor Relations section under Events.
  • Brooklyn is focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases.

MPM Expands its Team with the Appointment of RNA Expert and Leading Biotech Executive Pete Smith, PhD

Retrieved on: 
Tuesday, September 21, 2021
Professional Services, Oncology, Health, Finance, Pharmaceutical, Biotechnology, Biotechnology, Infection, RNA transfection, MPM, Partner (business rank), RNA, Head, Therapy, Inflammation, GlaxoSmithKline, Central nervous system, Merck, Sirna, Pharmacia, Drug development, Drug discovery, Doctor of Philosophy, Millennium, SVP, Industry, Pharmaceutical industry

MPM, a world-leading biotechnology investment firm with nearly three decades of experience creating and investing in early-stage therapeutics companies, today announced the recent appointment of leading biotech executive Pete Smith, PhD, to its team of MPM Entrepreneurs.

Key Points: 
  • MPM, a world-leading biotechnology investment firm with nearly three decades of experience creating and investing in early-stage therapeutics companies, today announced the recent appointment of leading biotech executive Pete Smith, PhD, to its team of MPM Entrepreneurs.
  • Pete brings a wealth of experience to MPM having spent more than thirty years in the pharmaceutical industry, including thirteen years at Millennium.
  • He brings extensive and proven experience in building and leading teams spanning discovery through development across multiple modalities.
  • At MPM, Pete will take a leading role in helping the team explore new opportunities, particularly in those in areas of new modalities, including RNA therapies.

aTyr Pharma Announces Closing of $86.3 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Monday, September 20, 2021
Sinclair Investments (UK) Ltd v Versailles Trade Finance Ltd, Exercise, RNA transfection, Syndicate, Security (finance), Form S-3, RBC Capital Markets, Sale, LIFE, Attention, U.S. Securities and Exchange Commission, ATyr Pharma, Biology, Form, LLC, SAN, Research, Minnesota, Telephone, Prospectus, Nicollet Mall, SEC, Vesey Street, GLOBE

The gross proceeds to aTyr from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are $86.3 million.

Key Points: 
  • The gross proceeds to aTyr from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are $86.3 million.
  • All of the shares sold in the offering were sold by aTyr.
  • Piper Sandler and RBC Capital Markets acted as joint book-running managers for the offering.
  • The offering was made pursuant effective registration statements, filed by aTyr with the Securities and Exchange Commission ("SEC").

PTC Therapeutics to Host Conference Call to Discuss Results of PTC518 Phase 1 Study for Huntington's Disease Program

Retrieved on: 
Monday, September 20, 2021
Blood, Therapy, Cerebrospinal fluid, RNA transfection, Huntington's disease, Movement, NASDAQ, Patient, Traffic barrier, PTC Therapeutics, LinkedIn, Neurological disorder, HTT, Twitter, Ageing, Disease, HD, Huntingtin, Brain, Cell, PTC, Mutation, Vaccine, Pharmaceutical industry

SOUTH PLAINFIELD, N.J., Sept. 20, 2021 /PRNewswire/ --PTC Therapeutics, Inc.(NASDAQ: PTCT) will host a conference call to discuss the positive results from the PTC518 Phase 1 healthy volunteer study.

Key Points: 
  • SOUTH PLAINFIELD, N.J., Sept. 20, 2021 /PRNewswire/ --PTC Therapeutics, Inc.(NASDAQ: PTCT) will host a conference call to discuss the positive results from the PTC518 Phase 1 healthy volunteer study.
  • During this call, the company will also provide an update on the PTC518 Phase 2 study, to be conducted in Huntington's disease patients, which PTC expects to initiate by the end of the year.
  • A live, listen-only audiocast will be available on the Events and Presentations page of the Investor section of PTC Therapeutics' website at www.ptcbio.com .
  • To learn more about PTC, please visit us at www.ptcbio.com and follow us on Instagram, Facebook, Twitter, and LinkedIn.

Europe miRNA Sequencing and Assay Market Forecast to 2027: Widening Range of MicroRNA Applications & Rise in Funding for Genomics Research - ResearchAndMarkets.com

Retrieved on: 
Monday, September 20, 2021
Health, Genetics, Science, Pharmaceutical, Research, MicroRNA, QIAGEN, RNA transfection, NGS, Miravirsen, Mirna, RNA, Degenerative disease, Therapy, CAGR, Center for Urban and Regional Analysis, Cancer, MiR-122, Phase, Genomics, Growth, Hepatitis, COVID-19, Severe acute respiratory syndrome coronavirus 2, Research, Santaris Pharma, HCV, Carcinogenesis, Animal, Vaccine, Pharmaceutical industry

The "Europe miRNA Sequencing and Assay Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Product, Technology, and End User" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe miRNA Sequencing and Assay Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Product, Technology, and End User" report has been added to ResearchAndMarkets.com's offering.
  • The widening application range of microRNAs and rise in funding for genomics research.
  • Therefore, rise in funding of genomic research to identify new molecules to diagnose and treat diseases, and consequent expansion of the range of applications of miRNAs are driving the growth of the miRNA sequencing and assay market in Europe.
  • Hence, the COVID-19 pandemic has been supporting the Europe miRNA sequencing and assay market growth.

CoImmune, Inc. to Participate in Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Retrieved on: 
Monday, September 20, 2021
Toxicity, B cell, Program, RNA transfection, RNA, Technology, GLOBE, Vaccine

DURHAM, N.C., Sept. 20, 2021 (GLOBE NEWSWIRE) -- CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today announced that Charles Nicolette, chief executive officer of CoImmune, will present a corporate update on September 23, 2021 at 9:05AM EDT during the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit.

Key Points: 
  • DURHAM, N.C., Sept. 20, 2021 (GLOBE NEWSWIRE) -- CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today announced that Charles Nicolette, chief executive officer of CoImmune, will present a corporate update on September 23, 2021 at 9:05AM EDT during the virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit.
  • Dr. Nicolette will review progress in development of the companys allogeneic CAR-CIK technology platform for the treatment of liquid and solid tumors and will be available to participate in one-on-one meetings with investors during the conference being held September 21-23, 2021.
  • Our allogeneic CAR-CIK technology platform for liquid and solid tumors is a variation on CAR-Ttherapy that promises enhanced efficacy with greatly reduced toxicity.
  • Our autologous RNA-loaded dendritic cell technology for solid tumorsuses amplified total tumor mRNA to program highly engineered dendritic cells to generate immune responses against neoantigens withoutthe need to identify them.

Dyne Therapeutics Presents New In Vivo Data for its Myotonic Dystrophy Type 1 Candidate (DYNE-101) Demonstrating Robust Splicing Correction During World Muscle Society 2021 Virtual Congress

Retrieved on: 
Monday, September 20, 2021
People, Mouse, Therapy, DM1, RNA transfection, Duchenne muscular dystrophy, ASO, RNA, Congress, Form 10-Q, Speech, Muscle, Security (finance), Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Patient, PMO, FORCE, LinkedIn, Heart, CTG, Transferrin, Toxicity, Kidney, GLOBE, WMS, Twitter, Human, Myopathy, Lists of diseases, Terminology, Phenotype, Digestion, Disease, DYN, DMD, Degenerative disease, COVID-19, Cognition, Dyne, Facioscapulohumeral muscular dystrophy, FSHD, Nasdaq, DMPK, SEC, Diaphragm, Pharmaceutical industry, Dietary supplement, Vaccine

WALTHAM, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, is presenting new in vivo data during the World Muscle Society (WMS) 2021 Virtual Congress demonstrating the ability of its myotonic dystrophy type 1 (DM1) candidate, DYNE-101, to target the nucleus and achieve knockdown of toxic DMPK RNA, foci reduction and correction of splicing in muscle tissues in the hTfR1/DMSXL mouse model.

Key Points: 
  • In addition, the subcellular fractionation data we generated reinforce that DM1 is a nuclear RNA-driven disease and that DYNE-101 effectively acts in the nucleus.
  • As a result of this altered splicing, people living with DM1 typically experience progressive weakness of skeletal, cardiac and smooth muscles.
  • TfR1, which is highly expressed on the surface of muscle cells, is required for iron transport into muscle cells.
  • Dyne links therapeutic payloads to its TfR1-binding fragment antibody (Fab) to develop targeted therapeutics for muscle diseases.

Adagio Therapeutics Provides COVID-19 Antibody Program Updates as well as Business Highlights and Second Quarter 2021 Financial Results

Retrieved on: 
Monday, September 20, 2021
Therapy, Review, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Conference, Private Securities Litigation Reform Act, Retail Industry Leaders Association, Growth, Scripps Research, IND, CRO, Safety, Research and development, SEC, Scripps, Food, Research, Vaccine, Exercise, General Administration of Sport of China, Disease, Emergency Use Authorization, Infection, RNA transfection, Partnership, Pharmacokinetics, Patient, FDA, Epitope, IDMC, Human, Severe acute respiratory syndrome coronavirus 2, Coronavirus, Forward-looking statement, GLOBE, Treatment, Half-life, Antibody, COVID-19, IPO, New, Nasdaq, Pharmaceutical industry

WALTHAM, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today reported updates on its lead COVID-19 antibody program, ADG20, as well as recent business highlights and second quarter 2021 financial results.

Key Points: 
  • WALTHAM, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today reported updates on its lead COVID-19 antibody program, ADG20, as well as recent business highlights and second quarter 2021 financial results.
  • ADG20 is a highly differentiated antibody that we are advancing through pivotal trials for both the treatment and prevention of COVID-19.
  • Research & development expenses including in-process research and development for the second quarter of 2021 were $37.6 million.
  • Selling, general & administrative expenses for the second quarter of 2021 were $7.1 million.

Matinas BioPharma Announces Accomplished Biotechnology Executive and Drug Developer Kathryn Penkus Corzo as Nominee to the Board of Directors

Retrieved on: 
Monday, September 20, 2021
LNC, The Company, Degenerative disease, Enactment, Cohort, Head, Private Securities Litigation Reform Act, EPA, Consultant, Form 10-K, Cystic fibrosis, SEC, Cystic Fibrosis Foundation, Biotechnology, DSMB, Vaccine, Board of directors, Takeda Pharmaceutical Company, Roche Diagnostics, Leadership, Technology, Survival, NYSE, Clinical trial, RNA transfection, Partnership, Eli Lilly, Risk, Solution, Therapy, Sale, DNA, Cancer, Management, Takeda, Company, Hoffmann-La Roche, DPA, R, Forward-looking statement, Cryptococcosis, GLOBE, Â, NTM, Infection, Patient, MCPHS University, Housing, Communities and Local Government Committee, Vice, Board, Research, Drug development, Mycosis, Pharmaceutical industry, Animal, Fine chemical

BEDMINSTER, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of critical therapeutics through its paradigm-changing lipid nanocrystal (LNC) platform delivery technology, today announced the nomination of Kathryn Penkus Corzo to stand for election to the Company’s Board of Directors at its 2021 Annual Meeting of Stockholders, scheduled for November 1, 2021.

Key Points: 
  • We are thrilled to nominate Kathryn to our Board of Directors, stated Herbert Conrad, Chairman of the Matinas BioPharma Board of Directors, and Chair of the Nominating and Governance Committee.
  • Ms. Corzo commented, I am honored to have been nominated to join the Matinas Board of Directors at such an exciting time for the Company.
  • On behalf of the Board of Directors and Matinas, I would like to thank Pat LePore for his service to the Company.
  • Kathryn Corzo is a biotechnology executive who has served in senior leadership roles for several leading biotechnology and pharmaceutical companies.